via its unique targeting of Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and tumor-associated antigens (TAAs).
Gammabody™ platform approach is fully modular, allowing for usage of Fc and existing antibodies
“Off the shelf” manufacturing
They combine a variety of traits to accomplish this including:
High potency with EC50s in low picomolar range
Potential for expansion of activated Vγ9Vδ2 (Vgamma9 Vdelta2) T cells
Avoids the detrimental co-activation of immune-suppressive cells, such as Tregs
Secretion of pro-inflammatory cytokines that attract and activate other cells within the immune system
Antigen-presenting capability, potentially triggering an adaptive immune reaction, enabling deep and durable responses
LAVA’s Gammabody™ platform acts through multiple mechanisms to induce selective, potent killing of tumor cells
Proof-of-principle of LAVA’s Gammabody™ approach has been established by in vitro, in vivo and ex vivo studies which demonstrate potent cell death in both tumor cell lines and patient-derived cells in both solid tumors and hematologic malignancies. Based on this data, LAVA has advanced its lead Gammabody™ drug candidates, LAVA-051 and LAVA-1207, into clinical development.